{
    "nct_id": "NCT04339751",
    "official_title": "The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease",
    "inclusion_criteria": "* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Adult patients (18 years and older)\n* Confirmed biochemical diagnosis of Cushing s disease (primary or recurrent) as evidenced by increased 24-hour urine free cortisol (UFC), normal or increased morning plasma Adrenocorticotropic Hormone (ACTH), and pituitary origin of excess ACTH.\n* Surgical candidate for resection of ACTH producing pituitary adenoma\n* Enrolled in 03-N-0164, Evaluation of Neurosurgical Disorders.\n* Able to provide written informed consent at the time of study enrollment.\n* Participants who are physically able to become pregnant must use an effective form of birth control from 14 days prior to enrollment through 6 months following the last dose of vorinostat. Participants who are able to father a child must use an effective form of birth control from Day 0 through 3 months following the last dose of vorinostat.\n\nEXCLUSION CRITERIA:\n\n* Patients who have been previously treated with vorinostat.\n* Patients who have received sellar radiation.\n* Significant medical illnesses that in the investigator s opinion cannot be adequately controlled or would compromise the patient s ability to tolerate this vorinostat.\n* Any history of cancer, unless in complete remission and off of all therapy for that disease for a minimum of 3 years.\n* History of thromboembolic disorder or deep vein thrombosis\n* Presence of abnormal hematological and biochemical parameters, (such as anemia or thrombocytopenia) as defined as:\n\n  * Neutrophil count < 1.5 K//micro L\n  * Hemoglobin < 8.0 g/dL.\n  * Hematocrit < 0.75x LLN (lower limit of normal)\n  * RBC count < 0.75x LLN\n  * Platelet count < 100 x 10^3 cells/micro L.\n  * Prothrombin time-international normalized ratio (PT-INR) > 1.5x ULN or Activated partial thromboplastin time (aPTT) > 1.5x ULN, with the exception of patients on prophylactic anticoagulation therapy\n  * Serum bilirubin level > 1.5x ULN.\n* Active infection being currently treated with systemic antibiotics.\n* Serious concurrent medical illness including renal failure (creatinine >3.0x - 6.0x ULN) liver failure (ALT/AST >5.0x - 20.0x ULN) or severe cardio-respiratory disease.\n* Pregnancy or lactation.\n* Presence of any disease that will obscure toxicity or dangerously alter drug metabolism (such as uncontrolled diabetes or bleeding disorders)\n* Currently receiving other investigational agents.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat, such as valproate.\n* Currently taking another HDACi, such as valproate.\n* Currently taking coumadin or its derivative anticoagulants.\n* Currently taking any other medication to reduce cortisol or ACTH levels\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}